Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

L-thyroxine no help for older patients with symptomatic SCH

Publish date:: May 8, 2020

Key clinical point: L-thyroxine treatment did not improve symptoms in patients aged 65 and older with subclinical hypothyroidism, compared with placebo.

Major finding: Even in subgroups of more symptomatic patients with SHT, L-thyroxine was no better than placebo at 1 year.

Study details: A post hoc analysis of 638 trial subjects with SHT randomized to placebo or L-thyroxine and followed 1 year.

Disclosures: None.

Citation:

De Montmollin et al. Ann Intern Med 2020; doi: 10.7326/M19-3193.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Endocrinology

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

No link shown between thyroid dysfunction and heart failure,

Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis,